Leerink Partnrs Has Positive Outlook of AVDL FY2027 Earnings

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Stock analysts at Leerink Partnrs raised their FY2027 earnings per share estimates for Avadel Pharmaceuticals in a report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of $1.50 per share for the year, up from their prior estimate of $1.40. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals’ FY2028 earnings at $2.15 EPS.

AVDL has been the subject of a number of other reports. Needham & Company LLC reduced their target price on shares of Avadel Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Thursday, January 9th. Piper Sandler decreased their price objective on Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating for the company in a report on Friday, January 10th. HC Wainwright restated a “buy” rating and issued a $21.00 target price (down previously from $25.00) on shares of Avadel Pharmaceuticals in a research note on Friday, January 10th. Oppenheimer raised their price target on shares of Avadel Pharmaceuticals from $29.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Finally, UBS Group cut their price objective on shares of Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, January 13th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Avadel Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $21.00.

Avadel Pharmaceuticals Trading Up 0.4 %

Avadel Pharmaceuticals stock opened at $7.69 on Friday. The company has a 50 day moving average of $9.77 and a 200-day moving average of $12.81. Avadel Pharmaceuticals has a twelve month low of $7.39 and a twelve month high of $19.09.

Avadel Pharmaceuticals (NASDAQ:AVDL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.03. The business had revenue of $50.00 million during the quarter, compared to analyst estimates of $48.43 million. Avadel Pharmaceuticals had a negative return on equity of 93.34% and a negative net margin of 52.53%. Avadel Pharmaceuticals’s quarterly revenue was up 624.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.41) EPS.

Insider Transactions at Avadel Pharmaceuticals

In other Avadel Pharmaceuticals news, CFO Thomas S. Mchugh purchased 5,000 shares of the stock in a transaction on Wednesday, December 11th. The shares were purchased at an average price of $10.49 per share, with a total value of $52,450.00. Following the completion of the transaction, the chief financial officer now directly owns 85,500 shares in the company, valued at $896,895. This represents a 6.21 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Linda Palczuk acquired 3,000 shares of the company’s stock in a transaction on Friday, December 6th. The stock was acquired at an average price of $10.19 per share, for a total transaction of $30,570.00. Following the purchase, the director now directly owns 66,400 shares of the company’s stock, valued at approximately $676,616. This trade represents a 4.73 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 55,579 shares of company stock worth $526,363 in the last 90 days. Corporate insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Wealth Effects LLC lifted its holdings in Avadel Pharmaceuticals by 4.9% during the 4th quarter. Wealth Effects LLC now owns 2,344,130 shares of the company’s stock valued at $24,637,000 after purchasing an additional 110,359 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Avadel Pharmaceuticals during the 3rd quarter worth about $642,000. State Street Corp boosted its holdings in shares of Avadel Pharmaceuticals by 42.5% during the 3rd quarter. State Street Corp now owns 1,623,302 shares of the company’s stock worth $21,290,000 after buying an additional 483,787 shares during the period. Barclays PLC grew its stake in Avadel Pharmaceuticals by 45.8% in the 3rd quarter. Barclays PLC now owns 392,691 shares of the company’s stock valued at $5,150,000 after buying an additional 123,430 shares during the last quarter. Finally, Lord Abbett & CO. LLC raised its holdings in Avadel Pharmaceuticals by 23.9% in the 3rd quarter. Lord Abbett & CO. LLC now owns 489,073 shares of the company’s stock valued at $6,414,000 after acquiring an additional 94,239 shares during the period. 69.19% of the stock is owned by institutional investors and hedge funds.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.